| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash (used in) provided by financing activities | 6,690 | -713 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -25,127 | -28,561 |
| Cash and cash equivalents at beginning of period | 99,854 | - |
| Cash and cash equivalents at end of period | 74,727 | - |
EyePoint Pharmaceuticals, Inc. (EYPT)
EyePoint Pharmaceuticals, Inc. (EYPT)